$AHR
American Healthcare REIT, Inc. Stock $ahr

$ahr Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000163297021000066 Filed on August 13, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$37.18M	$38.68M
YoY Change	-3.86%	27.34%
Cost Of Revenue	$250.4M	$14.44M
YoY Change	1634.01%	171.06%
Gross Profit	-$213.2M	$24.23M
YoY Change	-979.94%	-3.24%
Gross Profit Margin	-573.51%	62.66%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$24.66M	$7.893M
YoY Change	212.47%	21.62%
% of Gross Profit		32.57%
Operating Expenses
YoY Change
Operating Profit	$49.55M
YoY Change
Interest Expense	$18.49M	$4.974M
YoY Change	271.73%	30.65%
% of Operating Profit	37.32%
Other Income/Expense, Net	-$20.56M	-$2.786M
YoY Change	638.12%	-142.15%
Pretax Income	-$7.466M	-$1.116M
YoY Change	569.0%	-81.03%
Income Tax	$495.0K	$39.00K
% Of Pretax Income
Net Earnings	-$7.678M	-$946.0K
YoY Change	711.63%	-83.85%
Net Earnings / Revenue	-20.65%	-2.45%
Basic Earnings Per Share	-$0.04
Diluted Earnings Per Share	-$0.04
COMMON SHARES
Basic Shares Outstanding	179.6M shares
Diluted Shares Outstanding	179.6M shares

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$76.66M	$20.59M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$57.25M	$73.37M
YoY Change	-21.96%	11.78%
Long-Term Investments	$45.56M	$48.35M
YoY Change	-5.77%	1.27%
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$1.076B	$1.123B
YoY Change	-4.2%	17.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities	$543.7M	$551.4M
YoY Change	-1.39%	58.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$208.8M	-$159.4M
YoY Change	30.99%	50.46%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$528.9M	$568.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.076B	$1.123B
YoY Change	-4.2%	17.4%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$7.678M	-$946.0K
YoY Change	711.63%	-83.85%
Depreciation, Depletion And Amortization	$24.66M	$7.893M
YoY Change	212.47%	21.62%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Local Phone Number LocalPhoneNumber	270-9200
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001632970
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55775
	dei	Entity Registrant Name EntityRegistrantName	GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MD
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2887436
	dei	Entity Address Address Line1 EntityAddressAddressLine1	18191 Von Karman Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92612
	dei	City Area Code CityAreaCode	949
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	912467000	USD
CY2020Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	921580000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21336000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17411000	USD
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	1176000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	714000	USD
CY2021Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	1768000	USD
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2635000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	57251000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	64101000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14073000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14133000	USD
CY2021Q2	us-gaap	Other Assets OtherAssets	67710000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	72199000	USD
CY2021Q2	us-gaap	Assets Assets	1075781000	USD
CY2020Q4	us-gaap	Assets Assets	1092773000	USD
CY2021Q2	us-gaap	Secured Debt SecuredDebt	17572000	USD
CY2020Q4	us-gaap	Secured Debt SecuredDebt	17827000	USD
CY2021Q2	us-gaap	Line Of Credit LineOfCredit	482900000	USD
CY2020Q4	us-gaap	Line Of Credit LineOfCredit	476900000	USD
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	22929000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	23057000	USD
CY2021Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	1029000	USD
CY2020Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	1046000	USD
CY2021Q2	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	1174000	USD
CY2020Q4	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	1295000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	9971000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9904000	USD
CY2021Q2	us-gaap	Other Liabilities OtherLiabilities	8151000	USD
CY2020Q4	us-gaap	Other Liabilities OtherLiabilities	10387000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	543726000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	540416000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2593000	USD
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2618000	USD
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	736827000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	733192000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208759000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185047000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	528885000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	548958000	USD
CY2021Q2	us-gaap	Minority Interest MinorityInterest	577000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	781000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	529462000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	549739000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1075781000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1092773000	USD
CY2021Q2	us-gaap	Line Of Credit LineOfCredit	482900000	USD
CY2020Q4	us-gaap	Line Of Credit LineOfCredit	476900000	USD
CY2021Q2	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	21988000	USD
CY2020Q2	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	21842000	USD
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	43934000	USD
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	43305000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15194000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16834000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31089000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32915000	USD
CY2021Q2	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	37182000	USD
CY2020Q2	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	38676000	USD
	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	75023000	USD
	gahr	Revenuesand Government Grant Income From Cares Act RevenuesandGovernmentGrantIncomeFromCARESAct	76220000	USD
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	6129000	USD
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	5996000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	12153000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	11818000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14445000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14442000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29639000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	27459000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3659000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3840000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7406000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8288000	USD
CY2021Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2438000	USD
CY2020Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	8000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2752000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	17000	USD
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10597000	USD
CY2020Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12720000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	22999000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25250000	USD
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	37268000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	37006000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	74949000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	72832000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	4869000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	4974000	USD
	us-gaap	Interest Expense InterestExpense	9595000	USD
	us-gaap	Interest Expense InterestExpense	10284000	USD
CY2021Q2	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	1462000	USD
CY2020Q2	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	853000	USD
	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	2917000	USD
	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-3752000	USD
CY2021Q2	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	-199000	USD
CY2020Q2	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	0	USD
	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	-199000	USD
	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	0	USD
CY2021Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-193000	USD
CY2020Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1074000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1097000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1329000	USD
CY2021Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	9000	USD
CY2020Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	261000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	16000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	270000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3790000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2786000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7958000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12437000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3876000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1116000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7884000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9049000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-3876000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-1155000	USD
	us-gaap	Profit Loss ProfitLoss	-7884000	USD
	us-gaap	Profit Loss ProfitLoss	-9088000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-104000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-209000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-368000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-376000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3772000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-946000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7516000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8712000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81687564	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80402887	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81599875	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80352269	shares
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	541101000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	1393000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	41000	USD
CY2021Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1160000	USD
CY2021Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	31000	USD
CY2021Q2	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	-65000	USD
CY2021Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.10
CY2021Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	8152000	USD
CY2021Q2	gahr	Net Income Lossincluding Portion Attributableto Noncontrolling Interest Excluding Preferred Stock Dividend NetIncomeLossincludingPortionAttributabletoNoncontrollingInterestExcludingPreferredStockDividend	-3797000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	529462000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	577831000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	63000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	4997000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	41000	USD
CY2020Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	4643000	USD
CY2020Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	32000	USD
CY2020Q2	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	214000	USD
CY2020Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.10
CY2020Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	8022000	USD
CY2020Q2	gahr	Net Income Lossincluding Portion Attributableto Noncontrolling Interest Excluding Preferred Stock Dividend NetIncomeLossincludingPortionAttributabletoNoncontrollingInterestExcludingPreferredStockDividend	-1033000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	569002000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	549739000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5000	USD
	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	5499000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	84000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1874000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	55000	USD
	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	75000	USD
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.20
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16196000	USD
	gahr	Net Income Lossincluding Portion Attributableto Noncontrolling Interest Excluding Preferred Stock Dividend NetIncomeLossincludingPortionAttributabletoNoncontrollingInterestExcludingPreferredStockDividend	-7665000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	529462000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	590079000	USD
	gahr	Adjustments To Additional Paid In Capital Stock Issued Offering Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOfferingCosts	-62000	USD
	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	11434000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	84000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	4643000	USD
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	1250000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	32000	USD
	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	322000	USD
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.25
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	20041000	USD
	gahr	Net Income Lossincluding Portion Attributableto Noncontrolling Interest Excluding Preferred Stock Dividend NetIncomeLossincludingPortionAttributabletoNoncontrollingInterestExcludingPreferredStockDividend	-8883000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	569002000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-79000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-122000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-219000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-205000	USD
	us-gaap	Profit Loss ProfitLoss	-7884000	USD
	us-gaap	Profit Loss ProfitLoss	-9088000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22999000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25250000	USD
	gahr	Other Amortization OtherAmortization	1399000	USD
	gahr	Other Amortization OtherAmortization	1392000	USD
	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	-2104000	USD
	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	-2351000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	84000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	98000	USD
	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	-199000	USD
	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	0	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1097000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1329000	USD
	us-gaap	Increase Decrease In Other Financial Instruments Used In Operating Activities IncreaseDecreaseInOtherFinancialInstrumentsUsedInOperatingActivities	2917000	USD
	us-gaap	Increase Decrease In Other Financial Instruments Used In Operating Activities IncreaseDecreaseInOtherFinancialInstrumentsUsedInOperatingActivities	-3752000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-851000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1286000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1677000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1419000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1660000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2078000	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-47000	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	41000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	217000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	215000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	443000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-448000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13886000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19047000	USD
	us-gaap	Payments To Acquire And Develop Real Estate PaymentsToAcquireAndDevelopRealEstate	3375000	USD
	us-gaap	Payments To Acquire And Develop Real Estate PaymentsToAcquireAndDevelopRealEstate	67932000	USD
	us-gaap	Proceeds From Sale Of Real Estate Heldforinvestment ProceedsFromSaleOfRealEstateHeldforinvestment	6184000	USD
	us-gaap	Proceeds From Sale Of Real Estate Heldforinvestment ProceedsFromSaleOfRealEstateHeldforinvestment	0	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	2334000	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	4616000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	475000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-72548000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	293000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	8017000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	11000000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	137800000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	5000000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	55100000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	382000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	43000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2705000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3278000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	10772000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	10042000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1874000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4643000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1250000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	55000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	32000	USD
	gahr	Proceedsfrom Redeemable Noncontrolling Interests ProceedsfromRedeemableNoncontrollingInterests	126000	USD
	gahr	Proceedsfrom Redeemable Noncontrolling Interests ProceedsfromRedeemableNoncontrollingInterests	1118000	USD
	gahr	Paymentsto Redeemable Noncontrolling Interest PaymentstoRedeemableNoncontrollingInterest	7000	USD
	gahr	Paymentsto Redeemable Noncontrolling Interest PaymentstoRedeemableNoncontrollingInterest	72000	USD
	gahr	Payments For Proceeds From Security Deposits Financing Activities PaymentsForProceedsFromSecurityDepositsFinancingActivities	-12000	USD
	gahr	Payments For Proceeds From Security Deposits Financing Activities PaymentsForProceedsFromSecurityDepositsFinancingActivities	6000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9974000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58947000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	4387000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5446000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18125000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15846000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22512000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21292000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17411000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15290000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	714000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	556000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18125000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15846000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21336000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20585000	USD
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	1176000	USD
CY2020Q2	us-gaap	Restricted Cash RestrictedCash	707000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22512000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21292000	USD
	us-gaap	Interest Paid Net InterestPaidNet	8556000	USD
	us-gaap	Interest Paid Net InterestPaidNet	9428000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	44000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	18000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3016000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2309000	USD
	gahr	Tenant Improvement Overage TenantImprovementOverage	240000	USD
	gahr	Tenant Improvement Overage TenantImprovementOverage	625000	USD
	gahr	Noncash Or Part Noncash Acquisitions And Disposals Increase Decrease In Other Assets NoncashOrPartNoncashAcquisitionsAndDisposalsIncreaseDecreaseInOtherAssets	-16000	USD
	gahr	Noncash Or Part Noncash Acquisitions And Disposals Increase Decrease In Other Assets NoncashOrPartNoncashAcquisitionsAndDisposalsIncreaseDecreaseInOtherAssets	196000	USD
	gahr	Noncash Or Part Noncash Acquisitions And Disposals Increase Decrease In Accounts Payable And Accrued Expenses NoncashOrPartNoncashAcquisitionsAndDisposalsIncreaseDecreaseInAccountsPayableAndAccruedExpenses	-48000	USD
	gahr	Noncash Or Part Noncash Acquisitions And Disposals Increase Decrease In Accounts Payable And Accrued Expenses NoncashOrPartNoncashAcquisitionsAndDisposalsIncreaseDecreaseInAccountsPayableAndAccruedExpenses	201000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	10000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	11000	USD
	us-gaap	Stock Issued1 StockIssued1	5499000	USD
	us-gaap	Stock Issued1 StockIssued1	11434000	USD
CY2021Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	2689000	USD
CY2020Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	2651000	USD
CY2021Q2	gahr	Accruedstockholderservicingfee Accruedstockholderservicingfee	3392000	USD
CY2020Q2	gahr	Accruedstockholderservicingfee Accruedstockholderservicingfee	9270000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Organization and Description of Business </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Griffin-American Healthcare REIT IV, Inc., a Maryland corporation, invests in a diversified portfolio of healthcare real estate properties, focusing primarily on medical office buildings, skilled nursing facilities and senior housing facilities that produce current income. We also operate healthcare-related facilities utilizing the structure permitted by the REIT Investment Diversification and Empowerment Act of 2007, which is commonly referred to as a “RIDEA” structure (the provisions of the Internal Revenue Code of 1986, as amended, or the Code, authorizing the RIDEA structure were enacted as part of the Housing and Economic Recovery Act of 2008). We qualified to be taxed as a real estate investment trust, or REIT, under the Code for federal income tax purposes beginning with our taxable year ended December 31, 2016, and we intend to continue to qualify to be taxed as a REIT.</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We raised $754,118,000 through a best efforts initial public offering, or our initial offering, that commenced on February 16, 2016, and issued 75,639,681 aggregate shares of our Class T and Class I common stock. In addition, during our initial offering, we issued 3,253,535 aggregate shares of our Class T and Class I common stock pursuant to our distribution reinvestment plan, as amended, or the DRIP, for a total of $31,021,000 in distributions reinvested. Following the termination of our initial offering on February 15, 2019, we continued issuing shares of our common stock pursuant to the DRIP through a subsequent offering, or the 2019 DRIP Offering, which commenced on March 1, 2019. On March 18, 2021, our board of directors, or our board, authorized the suspension of the DRIP, effective as of April 1, 2021. As of June 30, 2021, a total of $46,970,000 in distributions were reinvested that resulted in 4,923,550 shares of our common stock being issued pursuant to the 2019 DRIP Offering. We collectively refer to the DRIP portion of our initial offering and the 2019 DRIP Offering as our DRIP Offerings. See Note 12, Equity — Distribution Reinvestment Plan, for a further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct substantially all of our operations through Griffin-American Healthcare REIT IV Holdings, LP, or our operating partnership. We are externally advised by Griffin-American Healthcare REIT IV Advisor, LLC, or our advisor, pursuant to an advisory agreement, as amended, or the Advisory Agreement, between us, our operating partnership and our advisor. The Advisory Agreement was effective as of February 16, 2016 and had a one-year initial term, subject to successive one-year renewals upon the mutual consent of the parties. The Advisory Agreement was last renewed pursuant to the mutual consent of the parties on February 11, 2021 and expires on February 16, 2022. Our advisor uses its best efforts, subject to the oversight and review of our board, to, among other things, provide asset management, property management, acquisition, disposition and other advisory services on our behalf consistent with our investment policies and objectives. Our advisor performs its duties and responsibilities under the Advisory Agreement as our fiduciary. Our advisor is 75.0% owned and managed by wholly owned subsidiaries of American Healthcare Investors, LLC, or American Healthcare Investors, and 25.0% owned by a wholly owned subsidiary of Griffin Capital Company, LLC, or Griffin Capital, or collectively, our co-sponsors. American Healthcare Investors is 47.1% owned by AHI Group Holdings, LLC, or AHI Group Holdings, 45.1% indirectly owned by Digital Bridge Group, Inc. (NYSE: DBRG) (formerly known as Colony Capital, Inc.), or Digital Bridge, and 7.8% owned by James F. Flaherty III, a former partner of Colony Capital, Inc. We are not affiliated with Griffin Capital, Griffin Capital Securities, LLC, or our dealer manager, Digital Bridge or Mr. Flaherty; however, we are affiliated with our advisor, American Healthcare Investors and AHI Group Holdings. </span></div><div style="margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently operate through four reportable business segments: medical office buildings, senior housing, senior housing — RIDEA and skilled nursing facilities. As of June 30, 2021, we owned 87 properties, comprising 92 buildings, or approximately 4,799,000 square feet of gross leasable area, or GLA, for an aggregate contract purchase price of $1,080,381,000. As of June 30, 2021, we also owned a 6.0% interest in a joint venture which owns a portfolio of integrated senior health campuses and ancillary businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to the ongoing coronavirus, or COVID-19, pandemic in the United States and globally, since March 2020, our residents, tenants, operating partners and managers have been materially impacted, and the prolonged economic impact remains uncertain. As the COVID-19 pandemic is still impacting the healthcare system to a degree, it continues to present challenges for us as an owner and operator of healthcare facilities. Since its outset, the impacts of the COVID-19 pandemic have been significant, rapidly and continuously evolving and may continue into the future, making it difficult to ascertain the long-term impact it will have on real estate markets in which we own and/or operate properties and our portfolio of investments. We have evaluated the impacts of the COVID-19 pandemic on our business thus far and incorporated information concerning the impact of COVID-19 into our assessments of liquidity, impairment and collectability from tenants and residents as of June 30, 2021. We will continue to monitor such impacts and will adjust our estimates and assumptions based on the best available information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed Merger with Griffin-American Healthcare REIT III, Inc. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, our board established a special committee of our board, or our special committee, which consists of all of our independent directors, to investigate and analyze strategic alternatives, including but not limited to, the sale of our assets, a listing of our shares on a national securities exchange, or a merger with another entity, including a merger with another unlisted entity that we expect would enhance our value. On June 23, 2021, we, our operating partnership, our wholly owned subsidiary, Continental Merger Sub, LLC, or merger sub, and Griffin-American Healthcare REIT III, Inc., or GAHR III, and its subsidiary Griffin-American Healthcare REIT III Holdings, LP, or GAHR III operating partnership, entered into an Agreement and Plan of Merger, or the Merger Agreement. Subject to the terms and conditions of the Merger Agreement, (i) GAHR III will be merged with and into merger sub, with merger sub being the surviving company, or the REIT Merger, and (ii) our operating partnership will be merged with and into GAHR III operating partnership, with GAHR III operating partnership being the surviving partnership and being renamed “American Healthcare REIT Holdings, LP”, or the Partnership Merger, and, together with the REIT Merger, the Merger.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the effective time of the REIT Merger, each issued and outstanding share of GAHR III’s common stock, $0.01 par value per share, will be converted into the right to receive 0.9266 of a share of our Class I common stock, $0.01 par value per share. Further, at the effective time of the Partnership Merger, (i) each unit of limited partnership interest in GAHR III operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger will be converted automatically into the right to receive 0.9266 of a Partnership Class I Unit, as defined in the agreement of limited partnership of the surviving partnership and (ii) each unit of limited partnership interest in our operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger will be converted automatically into the right to receive one unit of limited partnership interest of the surviving partnership of like class. Following the Merger, we (as combined with GAHR III, or the Combined Company) will be named “American Healthcare REIT, Inc.” The REIT Merger is intended to qualify as a “reorganization” under, and within the meaning of, Section 368(a) of the Internal Revenue Code of 1986, as amended.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Merger Agreement may be terminated by either us or GAHR III under certain circumstances, including but not limited to (in each case, with the prior approval of the special committee of the respective board of directors) (i) if the REIT Merger has not been consummated on or before 11:59 p.m. New York time on March 23, 2022; (ii) if the approval of the Merger by our stockholders or the stockholders of GAHR III is not obtained; or (iii) upon a material uncured breach of the respective obligations, covenants or agreements by the other party that would cause the closing conditions in the Merger Agreement not to be satisfied. The consummation of the Merger and the AHI Acquisition (as defined below) is subject to substantial conditions to closing and is not expected to close until the fourth quarter of 2021; therefore, our accompanying condensed consolidated financial statements do not include the Merger or the AHI Acquisition.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the Merger Agreement is terminated in connection with GAHR III’s acceptance of a Superior Proposal, as defined in the Merger Agreement, or due to GAHR III making a GAHR III Adverse Recommendation Change, as defined in the Merger Agreement, then GAHR III must pay us a termination fee of $50,654,000 and reimburse up to $4,000,000 of documented expenses incurred by us in connection with the Merger. If the Merger Agreement is terminated in connection with our acceptance of a Superior Proposal or due to us making a GAHR IV Adverse Recommendation Change, as defined in the Merger Agreement, then we must pay to GAHR III a termination fee of $23,028,000 and reimburse up to $4,000,000 of documented expenses incurred by GAHR III in connection with the Merger.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The parties to the Merger Agreement have agreed to certain limits on the conduct of their businesses between the signing of the Merger Agreement and the closing of the Merger. Generally, transactions that are not in the ordinary course of business require the consent of the other party. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also on June 23, 2021, GAHR III, GAHR III operating partnership, our co-sponsors, Platform Healthcare Investor T-II, LLC, Flaherty Trust, Jeffrey T. Hanson, our Chief Executive Officer and Chairman of the Board of Directors, Danny Prosky, our President and Chief Operating Officer, and Mathieu B. Streiff, our Executive Vice President, General Counsel, entered into a contribution and exchange agreement, or the Contribution Agreement, pursuant to which, among other things, GAHR III has agreed to acquire a newly formed entity, or the AHI Acquisition, that will own substantially all of the business and operations of one of our co-sponsors, American Healthcare Investors, as well as all of the equity interests in (i) Griffin-American Healthcare REIT III Advisor, LLC, a subsidiary of American Healthcare Investors that serves as the external advisor of GAHR III, and (ii) our advisor, such that GAHR III will become self-managed and (if the Merger does not occur) we will become indirectly managed by GAHR III. The AHI Acquisition is expected to close immediately prior to the consummation of the Merger. Following the consummation of the Merger, assuming the AHI Acquisition is consummated, the Combined Company will be an entirely self-managed company. The Merger is not subject to the consummation of the AHI Acquisition, such that the Merger may occur even if the AHI Acquisition does not. The parties to the Contribution Agreement also may elect to proceed with the AHI Acquisition even if the Merger is not consummated.</span></div>In addition, on June 23, 2021, in connection with the Merger, we amended the Advisory Agreement with our advisor, such that our advisor agreed to waive any acquisition fee due in connection with the REIT Merger. Except as set forth in such amendment to the Advisory Agreement, the terms of the Advisory Agreement shall continue in full force and effect.
	us-gaap	Stock Issued During Period Shares Dividend Reinvestment Plan StockIssuedDuringPeriodSharesDividendReinvestmentPlan	3253535	shares
	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	31021000	USD
CY2017	gahr	Advisory Agreement Term AdvisoryAgreementTerm	P1Y
CY2017	gahr	Advisory Agreement Term AdvisoryAgreementTerm	P1Y
CY2021Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
	gahr	Numberof Properties Acquiredfrom Unaffiliated Parties NumberofPropertiesAcquiredfromUnaffiliatedParties	87	Property
	gahr	Number Of Buildings Acquired From Unaffiliated Parties NumberOfBuildingsAcquiredFromUnaffiliatedParties	92	Building
CY2021Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	4799000	sqft
	gahr	Acquisition Aggregated Cost Of Acquired Properties Purchase Price AcquisitionAggregatedCostOfAcquiredPropertiesPurchasePrice	1080381000	USD
CY2021Q2	gahr	Termination Fee Receivable TerminationFeeReceivable	50654000	USD
CY2021Q2	gahr	Reimbursement Expenses Receivable ReimbursementExpensesReceivable	4000000	USD
CY2021Q2	gahr	Termination Fee Payable TerminationFeePayable	23028000	USD
CY2021Q2	gahr	Reimbursement Expenses Payable ReimbursementExpensesPayable	4000000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities, at the date of our condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include, but are not limited to, the initial and recurring valuation of certain assets acquired and liabilities assumed through property acquisitions, revenues, allowance for credit losses, impairment of long-lived and intangible assets and contingencies. </span></div>These estimates are made and evaluated on an on-going basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in material adverse ways, and those estimates could be different under different assumptions or conditions.
	us-gaap	Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts	<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tenant and Resident Receivables and Allowances</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Resident receivables, which are related to resident fees and services, are carried net of an allowance for credit losses. An allowance is maintained for estimated losses resulting from the inability of residents and payors to meet the contractual obligations under their lease or service agreements. Substantially all of such allowances are recorded as direct reductions of resident fees and services revenue as contractual adjustments provided to third-party payors or implicit price concessions in our accompanying condensed consolidated statements of operations. Our determination of the adequacy of these allowances is based primarily upon evaluations of historical loss experience, the residents’ financial condition, security deposits, cash collection patterns by payor and by state, current economic conditions, future expectations in estimating credit losses and other relevant factors. Tenant receivables, which are related to real estate revenue, and unbilled deferred rent receivables are reduced for uncollectible amounts, which are recognized as direct reductions of real estate revenue in our accompanying condensed consolidated statements of operations.</span></div>
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2238000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2086000	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Period Increase Decrease FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease	563000	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Period Increase Decrease FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease	541000	USD
	gahr	Financing Receivable Allowancefor Credit Loss Collectionsor Adjustments FinancingReceivableAllowanceforCreditLossCollectionsorAdjustments	-55000	USD
	gahr	Financing Receivable Allowancefor Credit Loss Collectionsor Adjustments FinancingReceivableAllowanceforCreditLossCollectionsorAdjustments	-74000	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	356000	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	39000	USD
CY2021Q2	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	1009421000	USD
CY2020Q4	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	1002859000	USD
CY2021Q2	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	96954000	USD
CY2020Q4	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	81279000	USD
CY2021Q2	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	912467000	USD
CY2020Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	921580000	USD
CY2021Q2	us-gaap	Depreciation Depreciation	7930000	USD
CY2020Q2	us-gaap	Depreciation Depreciation	7893000	USD
	us-gaap	Depreciation Depreciation	15844000	USD
	us-gaap	Depreciation Depreciation	15732000	USD
	gahr	Capitalized Acquisition Costsand Fees Additions CapitalizedAcquisitionCostsandFeesAdditions	94000	USD
	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	-199000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	57251000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	64101000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2654000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4877000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7137000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9633000	USD
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y10M24D
CY2020	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y9M18D
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	4896000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8647000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7390000	USD
CY2021Q2	gahr	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	24758000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	6195000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	5017000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	56903000	USD
CY2021Q2	us-gaap	Equity Method Investments EquityMethodInvestments	45556000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	46653000	USD
CY2021Q2	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	14499000	USD
CY2020Q4	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	12395000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	3562000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	9028000	USD
CY2021Q2	us-gaap	Deferred Costs Leasing Accumulated Amortization DeferredCostsLeasingAccumulatedAmortization	585000	USD
CY2020Q4	us-gaap	Deferred Costs Leasing Accumulated Amortization DeferredCostsLeasingAccumulatedAmortization	426000	USD
CY2021Q2	us-gaap	Deferred Costs Leasing Net DeferredCostsLeasingNet	3310000	USD
CY2020Q4	us-gaap	Deferred Costs Leasing Net DeferredCostsLeasingNet	2399000	USD
CY2021Q2	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	4338000	USD
CY2020Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	3397000	USD
CY2021Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	783000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1724000	USD
CY2021Q2	us-gaap	Other Assets OtherAssets	67710000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	72199000	USD
CY2021Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	471000	USD
CY2020Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	470000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	941000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	939000	USD
CY2021Q2	gahr	Joint Ventureunamortizedbasisdifference JointVentureunamortizedbasisdifference	16562000	USD
CY2020Q4	gahr	Joint Ventureunamortizedbasisdifference JointVentureunamortizedbasisdifference	16791000	USD
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18474000	USD
CY2021Q2	us-gaap	Secured Debt SecuredDebt	17572000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18766000	USD
CY2020Q4	us-gaap	Secured Debt SecuredDebt	17827000	USD
CY2021Q2	gahr	Number Of Fixed Rate Mortgage Loans Payable NumberOfFixedRateMortgageLoansPayable	3	MortgageLoan
CY2020Q4	gahr	Number Of Fixed Rate Mortgage Loans Payable NumberOfFixedRateMortgageLoansPayable	3	MortgageLoan
CY2020Q1	gahr	Payoffofmortgageloanpayable Payoffofmortgageloanpayable	7738000	USD
CY2020Q4	us-gaap	Secured Debt SecuredDebt	17827000	USD
CY2019Q4	us-gaap	Secured Debt SecuredDebt	26070000	USD
	gahr	Amortizationofdeferredfinancingcostsrelatedtomortgage Amortizationofdeferredfinancingcostsrelatedtomortgage	13000	USD
	gahr	Amortizationofdeferredfinancingcostsrelatedtomortgage Amortizationofdeferredfinancingcostsrelatedtomortgage	26000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-25000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-25000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	293000	USD
CY2020Q2	us-gaap	Secured Debt SecuredDebt	18104000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	8017000	USD
CY2021Q2	us-gaap	Secured Debt SecuredDebt	17572000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	315000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	651000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	680000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	711000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	5878000	USD
CY2021Q2	gahr	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	10239000	USD
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18474000	USD
CY2018Q4	gahr	Line Of Credit Facility Potential Extension Term LineOfCreditFacilityPotentialExtensionTerm	P12M
CY2018Q4	gahr	Line Of Credit Facility Number Of Potential Extensions LineOfCreditFacilityNumberOfPotentialExtensions	1	Extension
	gahr	Amortizationof Identified Intangible Liabilities AmortizationofIdentifiedIntangibleLiabilities	122000	USD
	gahr	Amortizationof Identified Intangible Liabilities AmortizationofIdentifiedIntangibleLiabilities	161000	USD
	gahr	Finite Lived Intangible Liabilities Useful Life FiniteLivedIntangibleLiabilitiesUsefulLife	P11Y10M24D
CY2020Q4	us-gaap	Line Of Credit LineOfCredit	476900000	USD
CY2020Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	530000000	USD
CY2021Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	530000000	USD
CY2021Q2	us-gaap	Line Of Credit LineOfCredit	482900000	USD
CY2021Q2	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	1462000	USD
CY2020Q2	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	853000	USD
	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	2917000	USD
	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-3752000	USD
CY2021Q2	gahr	Amortizationof Identified Intangible Liabilities AmortizationofIdentifiedIntangibleLiabilities	61000	USD
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2618000	USD
CY2020	gahr	Finite Lived Intangible Liabilities Useful Life FiniteLivedIntangibleLiabilitiesUsefulLife	P11Y7M6D
CY2020Q2	gahr	Amortizationof Identified Intangible Liabilities AmortizationofIdentifiedIntangibleLiabilities	69000	USD
CY2021Q2	gahr	Finite Lived Intangible Liabilities Amortization Expenses Remainder Of Fiscal Year FiniteLivedIntangibleLiabilitiesAmortizationExpensesRemainderOfFiscalYear	115000	USD
CY2021Q2	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Two FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearTwo	217000	USD
CY2021Q2	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Three FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearThree	207000	USD
CY2021Q2	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Four FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearFour	161000	USD
CY2021Q2	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Five FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearFive	123000	USD
CY2021Q2	gahr	Finite Lived Intangible Liabilities Amortization Expenses After Year Five FiniteLivedIntangibleLiabilitiesAmortizationExpensesAfterYearFive	351000	USD
CY2021Q2	gahr	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	1174000	USD
CY2019Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	1462000	USD
	gahr	Proceedsfromredeemablenoncontrollinginterest Proceedsfromredeemablenoncontrollinginterest	126000	USD
	gahr	Proceedsfromredeemablenoncontrollinginterest Proceedsfromredeemablenoncontrollinginterest	1118000	USD
	gahr	Paymentsto Redeemable Noncontrolling Interest PaymentstoRedeemableNoncontrollingInterest	7000	USD
	gahr	Paymentsto Redeemable Noncontrolling Interest PaymentstoRedeemableNoncontrollingInterest	72000	USD
	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	75000	USD
	gahr	Adjustments To Additional Paid In Capital Adjustment To Redeemable Noncontrolling Interests AdjustmentsToAdditionalPaidInCapitalAdjustmentToRedeemableNoncontrollingInterests	322000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-219000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-205000	USD
CY2021Q2	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2593000	USD
CY2020Q2	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2625000	USD
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	us-gaap	Stock Issued During Period Shares Dividend Reinvestment Plan StockIssuedDuringPeriodSharesDividendReinvestmentPlan	8177085	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	105000	shares
	gahr	Common Stock Repurchased During Period Under Share Repurchase Plan Shares CommonStockRepurchasedDuringPeriodUnderShareRepurchasePlanShares	2211338	shares
CY2021Q2	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	1393000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	4997000	USD
	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	5499000	USD
	us-gaap	Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan	77991000	USD
	us-gaap	Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan	72492000	USD
	us-gaap	Stock Issued During Period Shares Dividend Reinvestment Plan StockIssuedDuringPeriodSharesDividendReinvestmentPlan	8177085	shares
	us-gaap	Stock Issued During Period Shares Dividend Reinvestment Plan StockIssuedDuringPeriodSharesDividendReinvestmentPlan	7595594	shares
	gahr	Maximum Percentage Of Common Stock Repurchased During Period MaximumPercentageOfCommonStockRepurchasedDuringPeriod	0.050
CY2021Q2	gahr	Share Repurchase Plan Percentageof Priceper Share Condition Two ShareRepurchasePlanPercentageofPriceperShareConditionTwo	1
CY2021Q2	gahr	Stock Acquired Average Cost Per Share StockAcquiredAverageCostPerShare	9.89
CY2020Q2	gahr	Stock Acquired Average Cost Per Share StockAcquiredAverageCostPerShare	9.17
	gahr	Stock Acquired Average Cost Per Share StockAcquiredAverageCostPerShare	9.88
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2211338	shares
	gahr	Stock Acquired Average Cost Per Share StockAcquiredAverageCostPerShare	9.17
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2021771	shares
	gahr	Stock Repuchased During Period Value Under Share Repurchase Plan Value StockRepuchasedDuringPeriodValueUnderShareRepurchasePlanValue	20744000	USD
	gahr	Stock Repuchased During Period Value Under Share Repurchase Plan Value StockRepuchasedDuringPeriodValueUnderShareRepurchasePlanValue	18870000	USD
	gahr	Stock Acquired Average Cost Per Share StockAcquiredAverageCostPerShare	9.38
	gahr	Stock Acquired Average Cost Per Share StockAcquiredAverageCostPerShare	9.33
CY2021Q2	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	3312000	USD
CY2020Q2	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	3015000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	6445000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	7299000	USD
CY2021Q2	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	1029000	USD
CY2020Q4	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	1046000	USD
CY2021Q2	us-gaap	Secured Debt SecuredDebt	17572000	USD
CY2021Q2	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	20970000	USD
CY2020Q4	us-gaap	Secured Debt SecuredDebt	17827000	USD
CY2020Q4	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	22052000	USD
CY2021Q2	gahr	Linesofcreditandtermloannet Linesofcreditandtermloannet	482117000	USD
CY2021Q2	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	482931000	USD
CY2020Q4	gahr	Linesofcreditandtermloannet Linesofcreditandtermloannet	475176000	USD
CY2020Q4	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	477651000	USD
CY2021Q2	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	679000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P79Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P79Y6M
CY2020Q2	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1000000	USD
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1803000	USD
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1271000	USD
CY2021Q2	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	193000	USD
CY2020Q2	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	301000	USD
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	559000	USD
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	394000	USD
CY2021Q2	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	37000	USD
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	37000	USD
CY2021Q2	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2021Q2	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	872000	USD
CY2020Q2	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1301000	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2362000	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1665000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39000	USD
CY2021Q2	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	21988000	USD
CY2020Q2	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	21842000	USD
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	4860000	USD
CY2020Q2	us-gaap	Variable Lease Cost VariableLeaseCost	4814000	USD
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	43934000	USD
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	43305000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	9804000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	9269000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	32752000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	62663000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	58696000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	53151000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	47761000	USD
CY2021Q2	gahr	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	278887000	USD
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	533910000	USD
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	210000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	228000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	418000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	437000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0574
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0574
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	306000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	526000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	530000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	534000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	538000	USD
CY2021Q2	gahr	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	46565000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	48999000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	39028000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	9971000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2021Q2	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	21988000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15194000	USD
CY2021Q2	us-gaap	Revenues Revenues	37182000	USD
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	6129000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14445000	USD
CY2021Q2	gahr	Segmentnetoperatingincome Segmentnetoperatingincome	16608000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3659000	USD
CY2021Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2438000	USD
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10597000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	4869000	USD
CY2021Q2	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	1462000	USD
CY2021Q2	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	-199000	USD
CY2021Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-193000	USD
CY2021Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	9000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3790000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-3876000	USD
CY2020Q2	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	21842000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16834000	USD
CY2020Q2	us-gaap	Revenues Revenues	38676000	USD
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	5996000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14442000	USD
CY2020Q2	gahr	Segmentnetoperatingincome Segmentnetoperatingincome	18238000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3840000	USD
CY2020Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	8000	USD
CY2020Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12720000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	4974000	USD
CY2020Q2	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	853000	USD
CY2020Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1074000	USD
CY2020Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	261000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2786000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1116000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-1155000	USD
	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	43934000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31089000	USD
	us-gaap	Revenues Revenues	75023000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	12153000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29639000	USD
	gahr	Segmentnetoperatingincome Segmentnetoperatingincome	33231000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7406000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2752000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	22999000	USD
	us-gaap	Interest Expense InterestExpense	9595000	USD
	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	2917000	USD
	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	-199000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1097000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	16000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7958000	USD
	us-gaap	Profit Loss ProfitLoss	-7884000	USD
	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	43305000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32915000	USD
	us-gaap	Revenues Revenues	76220000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	11818000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	27459000	USD
	gahr	Segmentnetoperatingincome Segmentnetoperatingincome	36943000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8288000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	17000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25250000	USD
	us-gaap	Interest Expense InterestExpense	10284000	USD
	us-gaap	Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-3752000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1329000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	270000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12437000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9049000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39000	USD
	us-gaap	Profit Loss ProfitLoss	-9088000	USD
CY2021Q2	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	5000	USD
CY2021Q2	us-gaap	Assets Assets	1075781000	USD
CY2020Q4	us-gaap	Assets Assets	1092773000	USD
CY2021Q2	gahr	Concentration Risk Number Of States That Generated At Least Ten Percent Of Annualized Base Rent ConcentrationRiskNumberOfStatesThatGeneratedAtLeastTenPercentOfAnnualizedBaseRent	2	State
CY2021Q2	gahr	Minimum Percent Share Of Each State Annualized Base Rent That Company Owned MinimumPercentShareOfEachStateAnnualizedBaseRentThatCompanyOwned	0.100
CY2021Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2021Q2	gahr	Number Of Tenants With More Than Ten Percent Of Annual Base Rent NumberOfTenantsWithMoreThanTenPercentOfAnnualBaseRent	1	tenant
CY2021Q2	gahr	Minimum Percent Share Of Annualized Base Rent Accounted By Tenants MinimumPercentShareOfAnnualizedBaseRentAccountedByTenants	0.100
CY2020Q2	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	4000	USD
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	9000	USD
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	11000	USD

Files In Submission

Name	View Source	Status
0001632970-21-000066-index-headers.html	Edgar Link	pending
0001632970-21-000066-index.html	Edgar Link	pending
0001632970-21-000066.txt	Edgar Link	pending
0001632970-21-000066-xbrl.zip	Edgar Link	pending
ex311-gahr4x10xq2021xq2.htm	Edgar Link	pending
ex312-gahr4x10xq2021xq2.htm	Edgar Link	pending
ex321-gahr4x10xq2021xq2.htm	Edgar Link	pending
ex322-gahr4x10xq2021xq2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gahr-20210630.htm	Edgar Link	pending
gahr-20210630.xsd	Edgar Link	pending
gahr-20210630_cal.xml	Edgar Link	unprocessable
gahr-20210630_def.xml	Edgar Link	unprocessable
gahr-20210630_htm.xml	Edgar Link	completed
gahr-20210630_lab.xml	Edgar Link	unprocessable
gahr-20210630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AHR
American Healthcare REIT, Inc. Stock $ahr

2021 Q2 Form 10-Q Financial Statement

#000163297021000066 Filed on August 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AHR American Healthcare REIT, Inc. Stock $ahr

2021 Q2 Form 10-Q Financial Statement

#000163297021000066 Filed on August 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AHR
American Healthcare REIT, Inc. Stock $ahr